Bayer Roundup $7.25 Billion Settlement Over Non Hodgkin Lymphoma Cancer Claims

Bayer’s proposed $7.25 billion Roundup settlement grows out of a decade-long wave of lawsuits alleging that glyphosate—the active ingredient in Roundup, one of the world’s most widely used herbicides—can cause non-Hodgkin lymphoma (NHL) and that Monsanto (now owned by Bayer) failed to provide adequate warnings. The controversy intensified after the International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic” in 2015, even as the U.S. Environmental Protection Agency (EPA) has continued to say glyphosate is “not likely” carcinogenic when used as directed, leaving consumers caught between dueling scientific and regulatory assessments. Filed February 17, 2026 in St. Louis Circuit Court and awaiting approval, the deal would create a structured program for people already diagnosed with NHL and for “future claimants” who were exposed but may be diagnosed later, with tiered payments that generally range from about $10,000 to $165,000 (potentially higher with adjustments). The lawsuit and resulting settlement effort are significant because they aim to bring predictability to a sprawling mass tort that has produced some of the largest U.S. product-liability verdicts in recent memory, while also attempting to cover future disease claims that may not surface for years. Plaintiffs’ core argument is classic failure-to-warn/product-safety litigation: users say they relied on Roundup’s labeling and marketing and were not warned of a potential cancer risk; Bayer disputes causation and points to regulatory approvals. The timing is especially consequential because the U.S. Supreme Court has agreed to hear Monsanto Co. v. Durnell, a case testing whether the federal pesticide-labeling framework under FIFRA can preempt state-law failure-to-warn claims when the EPA has not required a cancer warning—an outcome that could sharply narrow or even derail many pending and future Roundup suits, making a court-approved settlement an attractive “certainty” option for many claimants and for Bayer. Broader implications extend beyond Roundup: the fight highlights how U.S. chemical and consumer-product disputes often turn on the tension between federal regulatory compliance and state tort law, and whether juries can impose liability for warnings not mandated by an agency label. It also echoes other mass-exposure settlements—where defendants trade large, capped payments for broad releases—while raising recurring concerns seen in prior Roundup proceedings, including how to fairly compensate future claimants, how to prevent fraudulent filings, and how settlement design can shape incentives to opt out and pursue individual trials that have sometimes yielded far higher awards than standardized class-program payouts.